| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to compounds of formula IA or IB or their pharmaceutically acceptable salts. The compounds of formula IA or IB possess sGC-stimulating activity. In formulas IA and IB , a circled B symbol means B ring, and B ring represents phenyl; n is equal to an integer specified in 0 to 1; each J B is independently specified in halogen; X is specified in N or C-H; D ring represents a 6-merous ring having X in formula IA, or a 5-merous ring having Y in formula IB; each Y is independently specified in C-H, C, N, O or S and independently substituted by J D when Y represents C or N; each of bonds between the two neighbouring atoms Y or between neighbouring Y and N in formula IB independently represents a single or double bond depending on whether Y is C, N, O or S, and D ring is aromatic; m is equal to an integer specified in 0 to 3; each J D is a substituted on a halogen or nitrogen atom of the ring and independently specified in halogen, -C(O)N(R D ) 2 , -N(R D ) 2 , -N(R d )C(O)R D , -N(R d )C(O)OR D , a 4-8-merous heterocyclic ring, wherein each specified 4-8-merous heterocyclic ring contains 1 to 2 heteroatoms independently specified in O, N or S; R C is specified in halogen, -CN, C 1-6 alkyl or C ring. The invention also refers to individual compounds and a pharmaceutical composition containing the compound of the invention or its pharmaceutically acceptable salt in an effective amount. n EFFECT: produced are the new compounds of formula IA or IB possessing sGC-stimulating activity. n 58 cl, 6 tbl, 12 ex |